The influence of choice of endpoint on trial size, duration, and interpretation of results was examined in patients with heart failure who were enrolled in BEST (Beta-blocker Evaluation of Survival Trial).
T he choice of endpoints in heart failure (HF) trials has evolved over the past 3 decades.
Initially, death from any cause was commonly used as the primary endpoint; however, with incremental improvements in therapy, it has become more common to use mortalityÀmorbidity composite outcomes (1) (2) (3) . In part, these reflect improving survival in HF and the resultant feasibility and affordability of conducting mortality trials.
However, incorporation of hospital admissions for HF in composites also recognizes the importance of these nonfatal events to the overall burden of HF and their economic significance (4) (5) (6) . Recently, cardiovascular (CV) mortality, rather than all-cause mortality, has been incorporated into composite outcomes. This recognizes the likely absence of the effect of novel treatments for HF on noncardiovascular death and the growing proportion of deaths From the a BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; attributable to noncardiovascular causes, because of the cumulative benefits of effective treatments on CV mortality (7) (8) (9) . Similarly, with improving survival and chronicity of HF, it has been suggested that analysis of all events, including repeat events, better reflects the overall burden of the condition than the conventional timeto-first-event analysis (10) (11) (12) (13) (14) . Recently, clinical practice has evolved, particularly in the United States, to attempt to manage worsening episodes of HF without formal admission to hospital. This potentially means that heart failure hospitalization (HFH) may no longer reflect the true extent of treatment failure. Consequently, it has been suggested that these nonhospitalized episodes should be included in composite outcomes (5, 15, 16) . However, there are few data on the frequency of these and whether they respond to study treatment in the same way as hospital admission.
We used the BEST (Beta-blocker Evaluation of Survival Trial) to examine the implications of this evolution in trial endpoints in HF with a reduced ejection fraction (17, 18) . BEST is of particular interest because information of emergency department (ED) visits and HFHs was collected systematically during the trial.
METHODS
STUDY DESIGN AND PATIENTS. BEST was a randomized double-blind trial of bucindolol in patients with HF, funded by the National Heart, Lung, and T i m e -t o -fi r s t -e v e n t a n a ly s e s . The baseline characteristics of patients who had a first isolated ED visit for HF, HFH, or CVD, or none of these events, were compared using analysis of variance for continuous variables and the chisquare test for categorical variables. HF duration was not normally distributed and thus was compared using the Kruskal-Wallis test.
The association between a first nonfatal event (ED visit for HF or HFH) and subsequent mortality was examined using time-updated Cox regression analysis with patients with neither event as the reference group. The association was adjusted for treatment assignment and baseline covariates, including age, sex, race, systolic blood pressure, heart rate, body mass index, LVEF, NYHA functional class, ischemic etiology, hypertension, diabetes, myocardial infarction, atrial fibrillation, previous implantable cardioverter-defibrillator, and serum creatinine. The treatment effect on the composite, and on the expanded composite and its components was examined using Cox regression analysis.
Assuming all-cause mortality, the composite endpoint, or the expanded composite as the endpoint, we examined the time taken to accrue a certain number of the assumed events. We also examined the sample size required to detect a 20% reduction in the assumed endpoint with bucindolol therapy using the log-rank test, assuming a 2-sided significance level of 5%, statistical power of 85%, equal allocation, 3-year uniform accrual period, a minimum follow-up of 1 year, and a maximum follow-up of 4 years.
RECURRENT EVENTS ANALYSIS. Recurrent events are commonly analyzed using count data methods (e.g., negative binomial regression) and time-toevent data methods (e.g., Andersen-Gill, Wei, Lin, were not admitted to hospital (48% and 49% of patients, respectively, who presented to the ED were not admitted) (HR: 0.84; 95% CI: 0.67 to 1.06; p ¼ 0.14). Overall, there were 586 ED visits for HF in the placebo group and 510 in the bucindolol group. Of these, 211 (36% of visits) and 176 (35% of visits), respectively, did not result in a proximate hospital admission ( Table 1) .
ADVERSE OUTCOME. The baseline characteristics of patients who experienced a CVD, HFH, or ED visit for HF (or none of these) are shown in Table 2 . Overall, patients who died had more characteristics associated with worse outcome (e.g., older age, lower blood pressure, estimated glomerular filtration rate, and Shen et al. Table 3) .
DISCUSSION
The purpose of this study was to illustrate the implications of the choice of primary endpoint in clinical Because of changing practice, it was suggested that composite outcomes be further expanded to include episodes of HF worsening that did not lead to formal hospital admission (5, 15, 16, 26, 27) . Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, United Kingdom. E-mail:
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